世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Actinic Keratosis Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Actinic Keratosis Treatment was estimated to be worth US$ 8764 million in 2024 and is forecast to a readjusted size of US$ 13144 million by 2031 with a CAGR of 6.1% during the... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global market for Actinic Keratosis Treatment was estimated to be worth US$ 8764 million in 2024 and is forecast to a readjusted size of US$ 13144 million by 2031 with a CAGR of 6.1% during the forecast period 2025-2031.Actinic keratosis (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. It's most commonly found on the face, lips, ears, back of your hands, forearms, scalp or neck. On the demand side, AK treatment is supported by multiple growth drivers: aging populations and UV-exposure related lifestyles expand the potential patient pool; increased public health emphasis on early detection and skin-cancer prevention encourages adoption of standardized diagnostic and field-treatment approaches. Technological and formulation innovations (improved topical vehicles, novel PDT carriers, and more convenient delivery formats), together with digital dermatology channels, provide firms opportunities for product line extension and deeper market penetration. Company annual reports highlight commercial focus on PDT and innovative topical prescriptions as a differentiation strategy. Despite clear opportunities, notable risks exist: many treatments are lesion-focused and can cause local irritation that reduces patient acceptance and follow-up; development of new drugs and devices entails long trial timelines, high R&D costs, and regulatory uncertainty; reimbursement frameworks and device approval pathways vary widely by market and may impede adoption of premium therapies. Failure to maintain regulatory transparency and real-world evidence can expose companies to regulatory scrutiny and erode market trust. Demand is shifting toward an integrated “treat + maintain” model, favoring low-irritation, high-adherence combination regimens, with stronger linkages between devices and prescription drugs and convergence of OTC skincare with prescription channels. Upstream key inputs include APIs for topical/systemic agents, photosensitizers and PDT pharmaceutical carriers, and optical/electronic components for laser/light devices. From a single-line capacity perspective, synthesis routes for certain photosensitizers and small-molecule APIs depend on specialized intermediates and catalysts, requiring lengthy capacity expansion lead times; high-end optical components are concentrated among a few suppliers, creating lead-time and quality control bottlenecks; natural extracts and adjunctive ingredients face scalability and standardization issues. Insufficient upstream investment risks supply shortages and cost volatility when demand spikes or regulations change. This report aims to provide a comprehensive presentation of the global market for Actinic Keratosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Actinic Keratosis Treatment by region & country, by Type, and by Application. The Actinic Keratosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Actinic Keratosis Treatment. Market Segmentation By Company DUSA Pharmaceuticals Novartis Perrigo LEO Pharma Bausch Health Taro Pharmaceutical Galderma (Nestle) Biofrontera Almirall Tolmar Pharmaceutical Biofrontera Novartis Sun Pharmaceutical Photocure ASA Segment by Type Destructive Treatment Photodynamic Therapy Topical Medications Others Segment by Application Hospital Clinic Others By Region North America United States Canada Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia-Pacific Europe Germany France U.K. Italy Netherlands Nordic Countries Rest of Europe Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Chapter Outline Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 2: Detailed analysis of Actinic Keratosis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Revenue of Actinic Keratosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world. Chapter 6: Revenue of Actinic Keratosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region. Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc. Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion. Table of Contents1 Market Overview1.1 Actinic Keratosis Treatment Product Introduction 1.2 Global Actinic Keratosis Treatment Market Size Forecast (2020-2031) 1.3 Actinic Keratosis Treatment Market Trends & Drivers 1.3.1 Actinic Keratosis Treatment Industry Trends 1.3.2 Actinic Keratosis Treatment Market Drivers & Opportunity 1.3.3 Actinic Keratosis Treatment Market Challenges 1.3.4 Actinic Keratosis Treatment Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Actinic Keratosis Treatment Players Revenue Ranking (2024) 2.2 Global Actinic Keratosis Treatment Revenue by Company (2020-2025) 2.3 Key Companies Actinic Keratosis Treatment Manufacturing Base Distribution and Headquarters 2.4 Key Companies Actinic Keratosis Treatment Product Offered 2.5 Key Companies Time to Begin Mass Production of Actinic Keratosis Treatment 2.6 Actinic Keratosis Treatment Market Competitive Analysis 2.6.1 Actinic Keratosis Treatment Market Concentration Rate (2020-2025) 2.6.2 Global 5 and 10 Largest Companies by Actinic Keratosis Treatment Revenue in 2024 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Actinic Keratosis Treatment as of 2024) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Destructive Treatment 3.1.2 Photodynamic Therapy 3.1.3 Topical Medications 3.1.4 Others 3.2 Global Actinic Keratosis Treatment Sales Value by Type 3.2.1 Global Actinic Keratosis Treatment Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Actinic Keratosis Treatment Sales Value, by Type (2020-2031) 3.2.3 Global Actinic Keratosis Treatment Sales Value, by Type (%) (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Clinic 4.1.3 Others 4.2 Global Actinic Keratosis Treatment Sales Value by Application 4.2.1 Global Actinic Keratosis Treatment Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Actinic Keratosis Treatment Sales Value, by Application (2020-2031) 4.2.3 Global Actinic Keratosis Treatment Sales Value, by Application (%) (2020-2031) 5 Segmentation by Region 5.1 Global Actinic Keratosis Treatment Sales Value by Region 5.1.1 Global Actinic Keratosis Treatment Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Actinic Keratosis Treatment Sales Value by Region (2020-2025) 5.1.3 Global Actinic Keratosis Treatment Sales Value by Region (2026-2031) 5.1.4 Global Actinic Keratosis Treatment Sales Value by Region (%), (2020-2031) 5.2 North America 5.2.1 North America Actinic Keratosis Treatment Sales Value, 2020-2031 5.2.2 North America Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031 5.3 Europe 5.3.1 Europe Actinic Keratosis Treatment Sales Value, 2020-2031 5.3.2 Europe Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031 5.4 Asia Pacific 5.4.1 Asia Pacific Actinic Keratosis Treatment Sales Value, 2020-2031 5.4.2 Asia Pacific Actinic Keratosis Treatment Sales Value by Region (%), 2024 VS 2031 5.5 South America 5.5.1 South America Actinic Keratosis Treatment Sales Value, 2020-2031 5.5.2 South America Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031 5.6 Middle East & Africa 5.6.1 Middle East & Africa Actinic Keratosis Treatment Sales Value, 2020-2031 5.6.2 Middle East & Africa Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Actinic Keratosis Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Actinic Keratosis Treatment Sales Value, 2020-2031 6.3 United States 6.3.1 United States Actinic Keratosis Treatment Sales Value, 2020-2031 6.3.2 United States Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Actinic Keratosis Treatment Sales Value, 2020-2031 6.4.2 Europe Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Actinic Keratosis Treatment Sales Value, 2020-2031 6.5.2 China Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031 6.5.3 China Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Actinic Keratosis Treatment Sales Value, 2020-2031 6.6.2 Japan Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Actinic Keratosis Treatment Sales Value, 2020-2031 6.7.2 South Korea Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Actinic Keratosis Treatment Sales Value, 2020-2031 6.8.2 Southeast Asia Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Actinic Keratosis Treatment Sales Value, 2020-2031 6.9.2 India Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031 6.9.3 India Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 DUSA Pharmaceuticals 7.1.1 DUSA Pharmaceuticals Profile 7.1.2 DUSA Pharmaceuticals Main Business 7.1.3 DUSA Pharmaceuticals Actinic Keratosis Treatment Products, Services and Solutions 7.1.4 DUSA Pharmaceuticals Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.1.5 DUSA Pharmaceuticals Recent Developments 7.2 Novartis 7.2.1 Novartis Profile 7.2.2 Novartis Main Business 7.2.3 Novartis Actinic Keratosis Treatment Products, Services and Solutions 7.2.4 Novartis Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.2.5 Novartis Recent Developments 7.3 Perrigo 7.3.1 Perrigo Profile 7.3.2 Perrigo Main Business 7.3.3 Perrigo Actinic Keratosis Treatment Products, Services and Solutions 7.3.4 Perrigo Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.3.5 Perrigo Recent Developments 7.4 LEO Pharma 7.4.1 LEO Pharma Profile 7.4.2 LEO Pharma Main Business 7.4.3 LEO Pharma Actinic Keratosis Treatment Products, Services and Solutions 7.4.4 LEO Pharma Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.4.5 LEO Pharma Recent Developments 7.5 Bausch Health 7.5.1 Bausch Health Profile 7.5.2 Bausch Health Main Business 7.5.3 Bausch Health Actinic Keratosis Treatment Products, Services and Solutions 7.5.4 Bausch Health Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.5.5 Bausch Health Recent Developments 7.6 Taro Pharmaceutical 7.6.1 Taro Pharmaceutical Profile 7.6.2 Taro Pharmaceutical Main Business 7.6.3 Taro Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions 7.6.4 Taro Pharmaceutical Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.6.5 Taro Pharmaceutical Recent Developments 7.7 Galderma (Nestle) 7.7.1 Galderma (Nestle) Profile 7.7.2 Galderma (Nestle) Main Business 7.7.3 Galderma (Nestle) Actinic Keratosis Treatment Products, Services and Solutions 7.7.4 Galderma (Nestle) Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.7.5 Galderma (Nestle) Recent Developments 7.8 Biofrontera 7.8.1 Biofrontera Profile 7.8.2 Biofrontera Main Business 7.8.3 Biofrontera Actinic Keratosis Treatment Products, Services and Solutions 7.8.4 Biofrontera Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.8.5 Biofrontera Recent Developments 7.9 Almirall 7.9.1 Almirall Profile 7.9.2 Almirall Main Business 7.9.3 Almirall Actinic Keratosis Treatment Products, Services and Solutions 7.9.4 Almirall Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.9.5 Almirall Recent Developments 7.10 Tolmar Pharmaceutical 7.10.1 Tolmar Pharmaceutical Profile 7.10.2 Tolmar Pharmaceutical Main Business 7.10.3 Tolmar Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions 7.10.4 Tolmar Pharmaceutical Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.10.5 Tolmar Pharmaceutical Recent Developments 7.11 Biofrontera 7.11.1 Biofrontera Profile 7.11.2 Biofrontera Main Business 7.11.3 Biofrontera Actinic Keratosis Treatment Products, Services and Solutions 7.11.4 Biofrontera Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.11.5 Biofrontera Recent Developments 7.12 Novartis 7.12.1 Novartis Profile 7.12.2 Novartis Main Business 7.12.3 Novartis Actinic Keratosis Treatment Products, Services and Solutions 7.12.4 Novartis Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.12.5 Novartis Recent Developments 7.13 Sun Pharmaceutical 7.13.1 Sun Pharmaceutical Profile 7.13.2 Sun Pharmaceutical Main Business 7.13.3 Sun Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions 7.13.4 Sun Pharmaceutical Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.13.5 Sun Pharmaceutical Recent Developments 7.14 Photocure ASA 7.14.1 Photocure ASA Profile 7.14.2 Photocure ASA Main Business 7.14.3 Photocure ASA Actinic Keratosis Treatment Products, Services and Solutions 7.14.4 Photocure ASA Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025) 7.14.5 Photocure ASA Recent Developments 8 Industry Chain Analysis 8.1 Actinic Keratosis Treatment Industrial Chain 8.2 Actinic Keratosis Treatment Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Actinic Keratosis Treatment Sales Model 8.5.2 Sales Channel 8.5.3 Actinic Keratosis Treatment Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療）の最新刊レポート
QYResearch社の 医療分野 での最新刊レポート
本レポートと同じKEY WORD（demand）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
